BioCryst says oral drug works for HAE attacks

BioCryst Pharma says its oral drug BCX7353 was effective in treating acute hereditary angioedema (HAE) attacks in a midstage trial, setting up a possible registration study as an alternative to current injectable or intravenous therapies.